At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 117 enrolled
Drug / intervention
Erythropoietin +1 moredrug
Likely dose
Erythropoietin 0.75µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Combined ErythroPoietin and Iron Therapy for AnemiC Patients With Severe Symptomatic Aortic Stenosis Undergoing Transcatheter Aortic Valve REplacement- The EPICURE Trial A Prospective Double Blind Randomized Trial
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec·interventional·Posted Mar 17, 2015·Updated Jul 17, 2018
In Brief
A Phase 3 clinical trial evaluating Erythropoietin and Placebo for Anemia and Aortic Stenosis. Completed, enrolled 117 participants across 1 site.
Detailed Summary
The objective of the study is to evaluate the efficacy of Erythropoietin (EPO) (+ iron) in reducing the rate of red blood cell transfusion requirements in patients with aortic stenosis undergoing transcatheter aortic valve replacement.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Aortic Stenosis
CountriesCanada
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
First PostedMar 2015
Primary CompletionJun 2015
Study CompletionJun 2016
TodayJul 2026
First PostedMar 17, 2015
Enrollment StartJun 1, 2012
Primary CompletionJun 1, 2015
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 11.3 years ago
Interventions
Erythropoietindrug
Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose
Placebodrug
Saline solution 0.9%